Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FFBW3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $42,553
Award facts
- Contract value 100% obligated
- $42,553.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $42,553.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on January 13, 2026, with an ultimate completion date of January 14, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The order will be fulfilled from the vendor's Park Ridge location and represents one of numerous delivery orders DMS Pharmaceutical Group has executed through the Defense Logistics Agency's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The prime contract, valued at $499,999,999 with a completion date of December 31, 2036, positions DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply a comprehensive range of branded and generic pharmaceuticals, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. The company's established performance on multiple delivery orders for specialty pharmaceuticals, including oncology treatments and emergency medications, demonstrates its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FFBW3?
SPE2DR26FFBW3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FFBW3 worth?
The government has obligated $42,553 on SPE2DR26FFBW3.
Is contract SPE2DR26FFBW3 an order under another contract?
Yes. SPE2DR26FFBW3 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBW3 competed?
The extent of competition for SPE2DR26FFBW3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award